Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.73 |
| ▸ | PPARG | P37231 | 2/20 | 0.57 |
| ▸ | PPARA | Q07869 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | ACACB | O00763 | 1/20 | 0.50 |
| ▸ | MMP3 | P08254 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL663059 | 1.00 | LDHA (0.73) | LDHAPPARGPPARASLC6A4ACACB | |
| SCHEMBL28745254 | 0.95 | LDHA (0.67) | LDHAPPARGPPARASLC6A4MMP3 | |
| SCHEMBL27795435 | 0.87 | LDHA (0.65) | LDHAPPARGPPARASLC6A4ACACB | |
| SCHEMBL15139563 | 0.86 | LDHA (0.65) | LDHAPPARGPPARASLC6A4ACACB | |
| SCHEMBL11237591 | 0.86 | TBXAS1 (0.59) | LDHAFFAR1 | |
| SCHEMBL23051836 | 0.85 | LDHA (0.62) | LDHAPPARGPPARASLC6A4ACACB | |
| SCHEMBL3832306 | 0.85 | LDHA (0.62) | LDHAPPARGPPARASLC6A4ACACB | |
| SCHEMBL490716 | 0.85 | LDHA (1.00) | LDHAPPARGPPARASLC6A4FFAR1 | |
| SCHEMBL8533256 | 0.84 | LDHA (0.61) | LDHAPPARGPPARASLC6A4MMP3 | |
| SCHEMBL13623718 | 0.84 | LDHA (0.61) | LDHASLC6A4ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-06-01 | — | — | US | disclosed |
| US-20230159592-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-05-25 | — | — | US | disclosed |
| US-20230144324-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-05-11 | — | — | US | disclosed |
| US-20180002709-A1 | RIBOSOME-MEDIATED INCORPORATION OF PEPTIDES AND PEPTIDOMIMETICS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-01-04 | — | — | US | disclosed |
| US-9657057-B2 | Dipeptide and tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160368946-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2016-12-22 | — | — | US | disclosed |
| US-9434761-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160031934-A1 | DIPEPTIDE AND TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-8980833-B2 | Tubulysine derivatives | R&D-BIOPHARMACEUTICALS GMBH (DE) | 2015-03-17 | — | — | US | disclosed |
| US-8735441-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8431571-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20130041008-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130035297-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
| US-20120129779-A1 | TUBULYSINE DERIVATIVES | R&D-BIOPHARMACEUTICALS GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| US-8030279-B2 | Tamandarin analogs and fragments thereof and methods of making and using | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002709-A1 | RIBOSOME-MEDIATED INCORPORATION OF PEPTIDES AND PEPTIDOMIMETICS | NPEPPS, DNPEP, AARS1 | LDHA 4109/4885PPARG 4434/4885PPARA 3737/4885 |
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | LDHA 3870/4885PPARG 1703/4885PPARA 1100/4885 |
| US-20230159592-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | LDHA 4338/4885PPARG 2394/4885PPARA 2167/4885 |
| US-20160031934-A1 | DIPEPTIDE AND TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, PEPD, DNPEP | LDHA 3690/4885PPARG 2247/4885PPARA 1667/4885 |
| US-20160368946-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTRL, ENPEP | LDHA 3237/4885PPARG 1490/4885PPARA 1254/4885 |
| US-20130041008-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | LDHA 3817/4885PPARG 4475/4885PPARA 4343/4885 |
| US-20120129779-A1 | TUBULYSINE DERIVATIVES | GLS, TPX2, HKDC1 | LDHA 1893/4885PPARG 4762/4885PPARA 4667/4885 |
| US-20230144324-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | LDHA 3384/4885PPARG 1396/4885PPARA 850/4885 |
| US-20130035297-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | LDHA 3817/4885PPARG 4475/4885PPARA 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.